Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

• Status: Unknown status
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: City Hospitals Sunderland NHS Foundation Trust
• Collaborator: Takeda
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Acute ischaemic stroke <72 hours from symptom onset (CT proven)

• Medically stable with no evidence of acute infection and not receiving antibiotic therapy

• Neurologically stable (no progression on NIHSS)

• Able to swallow unthickened fluids safely

• Mean BP (blood pressure) >120/70 in unaffected arm

Exclusion Criteria:

• Previous severe disability (Modified Rankin Score >2)

• Nursing home residents

• Previous history of congestive heart failure requiring treatment with ACE-Inhibitors or angiotensin receptor blockers

• Renal impairment (creatinine >200 mcgmol/L)

• Women of child bearing potential

• Minors <18 years of age

• History of dementia without ability to consent